Anzeige
Mehr »
Donnerstag, 03.07.2025 - Börsentäglich über 12.000 News
+210 % Kursgewinn Year to Date: Neuausrichtung nimmt Fahrt auf - jetzt exklusives CEO-Interview ansehen!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3EXC6 | ISIN: US00654J2069 | Ticker-Symbol: APE1
Siehe auch ADDEX THERAPEUTICS SA
Frankfurt
03.07.25 | 09:15
6,950 Euro
-6,71 % -0,500
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
ADDEX THERAPEUTICS SA ADR Chart 1 Jahr
5-Tage-Chart
ADDEX THERAPEUTICS SA ADR 5-Tage-Chart
RealtimeGeldBriefZeit
7,4508,05009:25

Aktuelle News zur ADDEX THERAPEUTICS SA ADR Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
ADDEX THERAPEUTICS SA ADR Aktie jetzt für 0€ handeln
MoAddex Therapeutics Ltd. - 6-K, Report of foreign issuer4
MoStalicla secures CHF 2M investment led by Addex for neuropsychiatric drug development2
MoAddex Therapeutics: Addex Leads CHF 2 Million Investment in Stalicla to Advance Precision Medicine in Neuropsychiatric Disorders252Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland - June 30, 2025 - Addex Therapeutics(SIX: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel...
► Artikel lesen
25.06.Addex Shareholders Approve All Board Proposals At 2025 AGM2
25.06.Addex Therapeutics: Addex Shareholders Approve All Resolutions at Annual General Meeting237Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, June 25, 2025 - Addex Therapeutics(SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric...
► Artikel lesen
20.06.Addex Therapeutics Ltd. - 6-K, Report of foreign issuer6
19.06.Earnings Call Transkript: Addex Therapeutics hebt Fortschritte im ersten Quartal 2025 hervor4
19.06.Addex sieht sich nach Q1 auf gutem Weg315Genf - Das Biotechunternehmen Addex ist gut in das neue Geschäftsjahr 2025 gestartet. Für den weiteren Geschäftsverlauf stehen dem Genfer Unternehmen liquide Mittel in Höhe von 2,8 Millionen Franken...
► Artikel lesen
19.06.Addex Therapeutics GAAP EPS of -CHF 0.01, income of CHF 0.07M2
19.06.Addex Therapeutics Q1 Loss Narrows Amid Sharply Lower Income3
19.06.Addex Therapeutics Reports Q1 2025 Financial Results and Provides Corporate Update517Strong cash position of CHF2.8 million at end of Q1 2025GABAB PAM chronic cough candidate demonstrated robust anti-tussive activity in disease models Regained rights to our phase 2 mGlu2 PAM asset,...
► Artikel lesen
18.06.Addex Therapeutics to Release Q1 2025 Financial Results and Host Conference Call on June 19, 2025238Geneva, Switzerland, June 18, 2025 - Addex Therapeutics(SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators...
► Artikel lesen
06.06.Addex Therapeutics Ltd. - 6-K, Report of foreign issuer6
06.06.Addex Therapeutics: Addex GABAB PAM Candidate Demonstrates Robust Anti-Tussive Activity in Multiple Chronic Cough Preclinical Models534Ad Hoc Announcement Pursuant to Art.?53 LR Geneva, Switzerland, June 6, 2025 - Addex Therapeutics(SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing...
► Artikel lesen
05.06.Addex Therapeutics: Addex to Present Positive GABAB PAM Chronic Cough Data at the 10th American Cough Conference339Geneva, Switzerland, June 5, 2025 - Addex Therapeutics(SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators...
► Artikel lesen
03.06.Addex Therapeutics: Addex Convenes Annual General Meeting 2025237Geneva, Switzerland, June 3, 2025 - Addex Therapeutics(SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric...
► Artikel lesen
15.05.Addex Therapeutics Ltd. - 20-F, Annual and transition report of foreign private issuers15
12.05.Addex Therapeutics Ltd. - 6-K, Report of foreign issuer10
12.05.Addex Therapeutics: Addex Partner Indivior Advances GABAB Positive Allosteric Modulator Program Successfully Through IND Enabling Studies418Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, May 12, 2025 - Addex Therapeutics(SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a...
► Artikel lesen
30.04.Addex Therapeutics: Addex Enters Option Agreement with Sinntaxis for an Exclusive License to Intellectual Property Covering the Use of mGlu5 Inhibitors in Brain Injury Recovery326Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, April 30, 2025 - Addex Therapeutics) for an exclusive license to intellectual property covering the use of metabotropic...
► Artikel lesen
Weiter >>
42 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1